We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation.
ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions – and highlights how this ecosystem is driving meaningful progress in patient care.
Original Source: https://bc-production.pressmatrix.com/de/profiles/98d522283e29/editions
Have a look at the VentureCapital Magazine: https://bc-production.pressmatrix.com/de/profiles/98d522283e29/editions/d0f1f2c05ace72a5f55d
Ähnliche Beiträge
ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care
January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.
ROTOP featured in VentureCapital Magazine
We are delighted to be featured in the latest
New Milestone: RoTecPSMA® Approved in Switzerland
RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced